Evolution Biotechnologies announces expansion into phage therapy - Evolution Biotechnologies
post-template-default,single,single-post,postid-7051,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Evolution Biotechnologies announces expansion into phage therapy

­Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced an important development in its operations, with the establishment of its therapeutic division. This will work to develop the therapeutic use of bacteria-killing viruses, or bacteriophages, an approach known as phage therapy. This is recognised as a highly promising approach to the control of antibiotic-resistant bacterial infections.

Dr. David Harper, the founder and Chief Officer of Evolution has unique experience in this area, having previously run the only modern clinical trial to demonstrate the efficacy of the approach, and demonstrated the effectiveness of phage therapy in controlling damaging infections in both companion dogs and humans.  The initial target will be the development of a treatment for ear infections in companion dogs, with additional markets following on. Work will be based at the planned company facility in Austin, Texas with a trials support unit based at the company’s existing Colworth site in the UK.

Dr. David Harper, Chief Officer of Evolution, said “I am delighted to be returning to the critically important area of fighting antimicrobial resistance. Phage therapy has been identified as one of the most promising approaches to addressing this crisis. By leveraging prior experience Evolution Biotechnologies is in a unique position to develop new medicines in this vital area.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on developing biological controls for of the house dust mite, with the company now expanding into phage therapy, a highly promising approach to controlling antimicrobial resistance. The development of additional technologies is planned for the future.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com

No Comments

Sorry, the comment form is closed at this time.